This trial is evaluating whether XmAb20717 will improve 1 primary outcome in patients with Endometrial Cancer. Measurement will happen over the course of 12 weeks.
This trial requires 150 total participants across 1 different treatment group
This trial involves a single treatment. XmAb20717 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"There has been a 3- to 5-fold increase in the incidence of U/EEC since 1970, and this increase is unlikely to be due entirely to changing demographics." - Anonymous Online Contributor
"Women with early endometrial cancer often discuss the option of treatment with their providers when their stage is ascertained. A variety of therapeutic options are available, including surgery, radiation therapy, chemotherapy, and hormonal therapy. In patients with advanced endometrial cancer, hormone therapy is the most widely used therapy." - Anonymous Online Contributor
"Current research suggests that treatment can be improved in certain people, while some people are not likely to benefit. It is of paramount importance that those who are likely to benefit from treatment, and how these patients can be identified, are fully involved in the research." - Anonymous Online Contributor
"Symptoms of endometrial cancer are common and are more likely to occur in the post-menopausal period. A vaginal examination is the most important aspect for the detection of endometrial cancer." - Anonymous Online Contributor
"Many possible etiologies have been proposed. Studies show that there is no correlation between exposure to asbestos and the development of endometrial cancer, but there may be an association between the presence of the BRCA allele and the development of endometrial cancer." - Anonymous Online Contributor
"[endometrial cancer](https://www.withpower.com/clinical-trials/endometrial-cancer) is a highly dangerous disease that is diagnosed in about 1 per 12,000 women in Australia each year. The lifetime risk of developing a endometrial cancer, from the age of 15 to 49, in those in whom the cancer arises is one in 20. A combination of screening with transvaginal ultrasonography annually or every 3 years and serum biomarker measurement during the age 60+ is therefore recommended. Copyright © 2015 John Wiley & Sons, Ltd." - Anonymous Online Contributor
"The research findings on [endometrial cancer](https://www.withpower.com/clinical-trials/endometrial-cancer) in recent years have not been very satisfying. Most new research has been focused only on specific cancer stages. Research has mainly focused on the stage, type and other details. Most of the research has been just descriptive, and not with a particular research aim. With more knowledge in the research, we can make some conclusions. Based on the last 50 years research, we can find that it is more advanced. There are many possibilities in medical treatments that have yet to be examined, like: the use of hormonal therapy, radiation therapy, cancer vaccine, and targeted therapies. There are more choices in the treatment options. Therefore, it is very important to have more research in the future." - Anonymous Online Contributor
"Overall, this data suggests MUC17 is widely expressed in EOC and that MUC17 targeting may represent a promising therapeutic strategy in patients with platinum naïve EOC. Phase I/II clinical trials assessing xmab20717 in EOC patients have been completed and results will be published." - Anonymous Online Contributor
"Xmab20817 has potent anti-proliferative, pro-apoptotic, and anti-mitotic activities in vitro models. Xmab20817 also exerts some anti-tumor activity in vivo. It might be useful to determine in the future how to use Xmab20717 as an adjuvant or prophylactic treatment agent in endometrial cancer." - Anonymous Online Contributor
"Although Xmab20717 is not suitable as a monotherapy for most patients, it shows acceptable activity when used with standard therapies, including chemotherapy-based regimes, radiotherapy, or combinations of modalities. Xmab20717 may be an effective immunotherapeutic strategy in combination with standard cancer treatments for many different types of cancers." - Anonymous Online Contributor
"According to current data, the most common cause of [endometrial cancer](https://www.withpower.com/clinical-trials/endometrial-cancer) is endometriosis. Additionally, endometriosis and primary ovarian cancer have been associated in several case-series and case papers. Endometriosis is an inflammatory disease that is usually associated with an increased risk of endometrial cancer, as well as ovarian cancer. It has been reported that up to 65% of endometrial cancer are associated with endometriosis. As a response to the disease, the body creates excess estrogen which is converted to more and more cancer. However, there are additional risk factors that increase the risk of endometrial cancer as well as ovarian cancer." - Anonymous Online Contributor
"Although there have been many trials of the effects of chemotherapy alone and combined with hormonal therapy after surgery for endometrial cancer, no conclusive trial has shown chemotherapy in combination with hormonal therapy alters the outcome for endometrial cancer patients. Patients with high-grade malignancy show significantly improved survival when this combination is administered to them. In addition, patients with low-grade endometrioid malignancies and those with tumors that have not invaded the myometrium show equal survival times when given cytotoxic-based chemotherapeutic treatments with the addition of hormonal therapy after surgery. Finally, patients with endometrial cancer and endometriosis also appear to benefit from chemotherapy. The treatment for endometriosis is an issue." - Anonymous Online Contributor